Kalytera Therapeutics Inc . ( TSX: V.KALY , OTCQB: KALTF , Forum ) on Thursday announced that it had entered into an agreement with Beetlebung Pharma, Ltd. for an option to acquire all rights to medical cannabis products in development by BPL for the treatment of both dermatologic diseases and women's health, such as psoriasis and menstrual cramps.
More information can be foundhere.
The Company was in the news recently when it filed a preliminary short form prospectus with securities regulatory authorities in Alberta, British Columbia and Ontario in connection with a proposed marketed offering of units of the Company for gross proceeds $3 to $10 million.
FULL DISCLOSURE: Kalytera Therapeutics Inc. is a paid client of Stockhouse Publishing.